Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Ipilimumab in Rare GI, Neuroendocrine, and Gynecological Cancers
NCT02923934Phase 2Completed
- Sponsor
- Olivia Newton-John Cancer Research Institute
- Start
- Aug 2017
- Primary completion
- Apr 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in cholangiocarcinoma (CCA), gallbladder cancer, duodenal cancer, Neuroendocrine Neoplasm (NEN), vaginal cancer, sponsored by Olivia Newton-John Cancer Research Institute. Started Aug 2017; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
cholangiocarcinoma (CCA)gallbladder cancerduodenal cancerNeuroendocrine Neoplasm (NEN)vaginal cancer
Beyond the preview
Go deeper on NCT02923934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02923934.